Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
What the film says
This trial is for multiple myeloma that has returned or not responded after at least two earlier lines of treatment, in tumors that carry NY-ESO-1.
The idea: give myeloma a new target for natural killer cells. The cells come from donated umbilical cord blood and are engineered with a receptor aimed at NY-ESO-1, together with interleukin-15. Patients receive chemotherapy, then one infusion of the cells. Those without a complete response may receive up to three more.
The first question is safety and the best cell dose. At MD Anderson in Houston, Muzaffar Qazilbash leads this early study.
Public record; not medical advice.
Sources behind this film
Multiple myeloma, returned or not responded, at least two earlier lines, tumors carry NY-ESO-1; Natural killer cells from donated umbilical cord blood, engineered with a receptor aimed at NY-ESO-1, together with interleukin-15 (IL-15 in the registry title); Chemotherapy first, then one infusion of the cells; Those without a complete response may receive up to three more (+2 more lines)
The drug
Primary Objectives: * Part A: To assess dose-limiting toxicity (DLT) and determine the safety and optimal cell dose of NY-ESO-1 TCR/IL-15 NK cells in patients with relapsed/refractory multiple myeloma. * Part B: To assess the day +90 overall response rate in patients treated at the optimal cell dose.
Secondary Objectives: * Assess day +180 progression-free survival (PFS). * Quantify the persistence of infused allogeneic donor TCR-transduced CB-derived NK cells in the recipient. * To conduct comprehensive immune reconstitution studies. * To obtain preliminary data on quality of life and patient experience. * Assess duration of response (DOR) Secondary end points * Day +180 PFS rate; * NY-ESO-1 TCR/IL-15 NK cell numbers in peripheral blood vs time profile; * Characterization of lymphocyte populations at various time points; * PROMIS-29 quality of life questionnaire score. * Duration of response
The study
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.